CORRIGENDUM

Anti-Breast Cancer Effect of 2-Dodecyl-6-Methoxycyclohexa-2,5-Diene-1,4-Dione in vivo and in vitro Through MAPK Signaling Pathway [Corrigendum]

Zhou X, Wu X, Qin L, et al. *Drug Des Devel Ther.* 2020;14:2667–2684.

The authors have advised when preparing the images for [Figure 5A](#) on page 2675, the incorrect image was used for the 0 h DMDD H group. This inadvertently led to the duplication of images for the DMDD M group and DMDD H group. The correct [Figure 5](#) is shown below.

The authors have also advised the incorrect image was used for [Figure 14C](#) on page 2682 which inadvertently led to the duplication of images for RAF1 in [Figure 14A](#) and GAPDH in [Figure 14C](#). The correct [Figure 14](#) is shown below.

The authors apologize for these errors and advise they do not affect the results of the paper.

Figure 5 Effect of DMDD on migration and invasion of 4T1 cells.

Notes: (A and B) The migration rates of 4T1 cells treated with DMDD for 24 hours were detected by the Scratch test. (C and D) The number of invasive 4T1 cells treated with DMDD for 24 hours was detected by Transwell assay. Data are presented as mean $\pm$ SD of three experiments. ** $P < 0.01$, DMDD vs control). DMDD L group: 6 μ M; DMDD M group: 8 μ M; DMDD H group: 10 μ M.

Figure 14 Detection results of MAPK pathway-related proteins in breast cancer tumor tissues.

Notes: (A and B) The migration rates of 4T1 cells treated with DMDD for 24 hours were detected by the Scratch test. (C and D) The number of invasive 4T1 cells treated with DMDD for 24 hours was detected by Transwell assay. Data are presented as mean $\pm$ SD of three experiments. ** $P < 0.01$, DMDD vs control). DMDD L group: 6 μ M; DMDD M group: 8 μ M; DMDD H group: 10 μ M.

Notes: (A–L) The WB image and relative protein expression of p-RAF1, p-MEK, p-ERK, p-p38, Bax and Bcl-2. Data are presented as mean $\pm$ SD of three experiments, $n=3$. (* $P < 0.05$, ** $P < 0.01$, vs model group).

Drug Design, Development and Therapy

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also

been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/drug-design-development-and-therapy-journal>

Dovepress